Haisen Pharm released its performance for the first three quarters, with a net profit attributable to the parent company of 88.2096 million yuan, an increase of 1.45%

Haisen Pharm released its Q3 2025 report, with operating revenue for the first three quarters at 359 million yuan, a year-on-year increase of 12.13%. The net profit attributable to the parent company was 88.2096 million yuan, a year-on-year increase of 1.45%. The net profit after deducting non-recurring gains and losses was 84.758 million yuan, a year-on-year decrease of 1.56%. The basic earnings per share were 0.59 yuan